Last updated: July 26, 2024
Sponsor: University of Missouri-Columbia
Overall Status: Active - Enrolling
Phase
1
Condition
Parathyroid Disease
Parathyroid Disorders
Hyperparathyroidism
Treatment
Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Bupivacaine Hydrochloride-EPINEPHrine
Lidocaine Epinephrine
Clinical Study ID
NCT04085913
2014881
Ages > 18 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients over the age of 18 years Patients requiring parathyroid/thyroid surgerybased on the standard of care English as primary language
Exclusion
Exclusion Criteria:
- Patients under the age of 18 years Patients with previous history of opioid abusePatients with a true allergy to any local anesthetic Patients with a true allergy toany opioid
Study Design
Total Participants: 100
Treatment Group(s): 3
Primary Treatment: Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Phase: 1
Study Start date:
September 30, 2019
Estimated Completion Date:
July 31, 2025
Study Description
Connect with a study center
University of Missouri
Columbia, Missouri 65212
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.